Dabur Pharma gets USFDA approval for selling ‘Mitoxantrone HCL’

Dabur Pharma Ltd's oncology unit has informed that the company has received the approval from US Food and Drug Administrator (USFDA) for selling 'Mitoxantrone Hydrochloride in various strengths’.

Dabur Pharma Ltd operates in Europe and other overseas markets through its fully-owned subsidiary, Dabur Oncology Plc.

The drug is indicated for reducing neurologic disability and /or the frequency of clinical relapses in patients with secondary chronic progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses).

Tagged with